Go Pro
→ The 2026 beginners Guide to Gold IRAs (From Goldco Direct, LLC) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$15.47
+2.3%		$14.03
$10.03
▼
$17.35
$27.36B0.0893,191 shs78,025 shs
H. Lundbeck A/S stock logo
HLUYY
H. Lundbeck A/S
$22.00
0.0%		$22.00
$10.00
▼
$31.55
$21.91B0.681,758 shs7,500 shs
Merck KGaA stock logo
MKGAF
Merck KGaA
$166.60
+1.8%		$163.93
$116.68
▼
$175.56
$21.53B0.96602 shs470 shs
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$14.94
-9.5%		$14.74
$10.27
▼
$18.67
$7.75B0.33597 shs197 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
+2.31%+3.48%+12.10%+16.93%+38.13%
H. Lundbeck A/S stock logo
HLUYY
H. Lundbeck A/S
0.00%0.00%0.00%0.00%0.00%
Merck KGaA stock logo
MKGAF
Merck KGaA
+1.77%+5.34%-2.34%+1.72%+29.55%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
-9.45%-5.80%+0.54%+2.68%+22.26%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$15.47
+2.3%		$14.03
$10.03
▼
$17.35
$27.36B0.0893,191 shs78,025 shs
H. Lundbeck A/S stock logo
HLUYY
H. Lundbeck A/S
$22.00
0.0%		$22.00
$10.00
▼
$31.55
$21.91B0.681,758 shs7,500 shs
Merck KGaA stock logo
MKGAF
Merck KGaA
$166.60
+1.8%		$163.93
$116.68
▼
$175.56
$21.53B0.96602 shs470 shs
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$14.94
-9.5%		$14.74
$10.27
▼
$18.67
$7.75B0.33597 shs197 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
+2.31%+3.48%+12.10%+16.93%+38.13%
H. Lundbeck A/S stock logo
HLUYY
H. Lundbeck A/S
0.00%0.00%0.00%0.00%0.00%
Merck KGaA stock logo
MKGAF
Merck KGaA
+1.77%+5.34%-2.34%+1.72%+29.55%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
-9.45%-5.80%+0.54%+2.68%+22.26%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
2.50
Moderate BuyN/AN/A
H. Lundbeck A/S stock logo
HLUYY
H. Lundbeck A/S
0.00
N/AN/AN/A
Merck KGaA stock logo
MKGAF
Merck KGaA
0.00
N/AN/AN/A
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest OPHLF, ALPMY, HLUYY, and MKGAF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2026
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/13/2026
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/23/2026
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$14.21B1.97$2.32 per share6.67$6.68 per share2.32
H. Lundbeck A/S stock logo
HLUYY
H. Lundbeck A/S
$2.59B8.45$3.36 per share6.54$14.60 per share1.51
Merck KGaA stock logo
MKGAF
Merck KGaA
$22.72B0.95$50.18 per share3.32$212.00 per share0.79
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$3.43B2.05$1.35 per share11.09$11.70 per share1.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$1.92B$1.3111.7711.90N/A16.01%25.89%12.69%10/29/2026 (Estimated)
H. Lundbeck A/S stock logo
HLUYY
H. Lundbeck A/S
$209.69M$0.8825.007.72N/A6.74%13.74%7.16%N/A
Merck KGaA stock logo
MKGAF
Merck KGaA
$3.06B$6.8125.4415.79N/A12.60%10.17%5.74%11/12/2026 (Estimated)
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
$463.46M$1.0514.2316.42N/A15.02%9.77%7.63%10/29/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.291.87%N/A22.14%N/A
H. Lundbeck A/S stock logo
HLUYY
H. Lundbeck A/S
$0.200.91%N/A22.73%N/A
Merck KGaA stock logo
MKGAF
Merck KGaA
N/AN/AN/AN/AN/A
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.17
1.17
0.90
H. Lundbeck A/S stock logo
HLUYY
H. Lundbeck A/S
0.32
1.15
0.71
Merck KGaA stock logo
MKGAF
Merck KGaA
0.27
1.31
0.84
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
0.08
3.28
2.56

Institutional Ownership

CompanyInstitutional Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
H. Lundbeck A/S stock logo
HLUYY
H. Lundbeck A/S
N/A
Merck KGaA stock logo
MKGAF
Merck KGaA
0.10%
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/A

Insider Ownership

CompanyInsider Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
H. Lundbeck A/S stock logo
HLUYY
H. Lundbeck A/S
N/A
Merck KGaA stock logo
MKGAF
Merck KGaA
N/A
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
14,0991.81 billionN/ANot Optionable
H. Lundbeck A/S stock logo
HLUYY
H. Lundbeck A/S
5,348995.74 millionN/ANot Optionable
Merck KGaA stock logo
MKGAF
Merck KGaA
62,908129.24 millionN/ANot Optionable
Ono Pharmaceutical Co. stock logo
OPHLF
Ono Pharmaceutical
4,287469.91 millionN/ANot Optionable

Recent News About These Companies

Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases
September 1 at 9:00 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20260901390619/en/ono-pharma-enters-into-a-drug-discovery-partnership-with-aitia-in-neurological-diseases/
Ono Pharma’s New Cancer Trial Adds Early-Stage Upside—and Risk—for OPHLF Investors
August 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ono-pharmas-new-cancer-trial-adds-early-stage-upside-and-risk-for-ophlf-investors?utm_source=marketbeat.com&utm_medium=referral
Are Investors Undervaluing Ono Pharmaceutical Co. (OPHLF) Right Now?
August 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2967495/are-investors-undervaluing-ono-pharmaceutical-co-ophlf-right-now?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_2-2967495
Ono Pharmaceutical Co. (OPHLF) Q1 Earnings and Revenues Top Estimates
July 31, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2965375/ono-pharmaceutical-co-ophlf-q1-earnings-and-revenues-top-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2965375
Ono Pharma Halts Early Lymphoma Trial, Raising Fresh Questions for Investors
July 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ono-pharma-halts-early-lymphoma-trial-raising-fresh-questions-for-investors?utm_source=marketbeat.com&utm_medium=referral
Earnings Preview: Ono Pharmaceutical Co. (OPHLF) Q1 Earnings Expected to Decline
July 27, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2961096/earnings-preview-ono-pharmaceutical-co-ophlf-q1-earnings-expected-to-decline?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_9-2961096
Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?
July 27, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2960790/strength-seen-in-ono-pharmaceutical-co-ophlf-can-its-9-2-jump-turn-into-more-strength?cid=cs-stocknewsapi-ft-tale_of_the_tape|daily_price_change_5%-2960790
Ono’s New GIST Study Puts Early‑Stage Oncology Back in Focus for OPHLF Investors
July 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/onos-new-gist-study-puts-earlystage-oncology-back-in-focus-for-ophlf-investors?utm_source=marketbeat.com&utm_medium=referral
Should Value Investors Buy Ono Pharmaceutical Co. (OPHLF) Stock?
July 13, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2952318/should-value-investors-buy-ono-pharmaceutical-co-ophlf-stock?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_2-2952318
Ono Pharmaceutical Co. (OPHLF) moves 10.4% higher: Will this strength last?
July 7, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/ono-pharmaceutical-co-ophlf-moves-104-higher-will-this-strength-last/ar-AA27nMPr
Ono Pharmaceutical Co. (OPHLF) Moves 10.4% Higher: Will This Strength Last?
July 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2949057/ono-pharmaceutical-co-ophlf-moves-10-4-higher-will-this-strength-last?cid=cs-stocknewsapi-ft-tale_of_the_tape|daily_price_change_5%-2949057
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting
June 1, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260601543914/en/Ono-Pharma-Announces-Oral-Presentation-of-New-Data-from-the-Phase-2-Clinical-Study-of-ONO-4578-EP4-antagonist-in-Certain-Gastric-Cancers-at-the-ASCO-2026-Annual-Meeting/
Analysts Are Neutral on These Healthcare Stocks: CSL (CMXHF), ONO Pharmaceutical Co (OPHLF)
June 1, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2233396/analysts-are-neutral-on-these-healthcare-stocks-csl-cmxhf-ono-pharmaceutical-co-ophlf/
Ono’s Real-World Tirabrutinib Study in Taiwan Reaches Completion, Setting Up a New Catalyst for OPHLF
May 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/onos-real-world-tirabrutinib-study-in-taiwan-reaches-completion-setting-up-a-new-catalyst-for-ophlf?utm_source=marketbeat.com&utm_medium=referral
Inhibrx cancer drug reportedly drawing interest of Merck and rivals
April 22, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/inhibrx-cancer-drug-reportedly-drawing-interest-of-merck-and-rivals/ar-AA21tfGs
Pfizer wins full FDA approval for Braftovi in colorectal cancer
February 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4556095-pfizer-wins-full-fda-approval-braftovi
ONO Pharmaceutical Posts Strong Profit Growth in Q3 FY2025 and Maintains Full-Year Outlook
February 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OPHLF/pressreleases/37371258/ono-pharmaceutical-posts-strong-profit-growth-in-q3-fy2025-and-maintains-full-year-outlook/
Ono Pharmaceutical Co., Ltd. (OPHLY) Presents at 44th Annual J.P.
January 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4859884-ono-pharmaceutical-co-ltd-ophly-presents-at-44th-annual-j-p-morgan-healthcare-conference
Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical
January 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/scenic-biotech-enters-license-research-100000020.html
Has Ono Pharmaceutical’s 2025 Share Price Rally Left Limited Upside?
December 9, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/ono-pharmaceutical-2025-share-price-031023889.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astellas Pharma stock logo

Astellas Pharma OTCMKTS:ALPMY

$15.47 +0.35 (+2.31%)
As of 09/3/2026 03:59 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

H. Lundbeck A/S stock logo

H. Lundbeck A/S OTCMKTS:HLUYY

$22.00 -0.01 (-0.02%)
As of 08/9/2022

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Merck KGaA stock logo

Merck KGaA OTCMKTS:MKGAF

$166.60 +2.89 (+1.77%)
As of 09/3/2026 03:53 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Ono Pharmaceutical stock logo

Ono Pharmaceutical OTCMKTS:OPHLF

$14.94 -1.56 (-9.45%)
As of 09/3/2026 03:05 PM Eastern

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas